Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

被引：0
|
作者：
Chatziralli, Irini [1 ,2 ]
Theodossiadis, George [3 ]
Moschos, Marilita [4 ]
Chatzirallis, Alexandros [2 ]
Mitropoulos, Panagiotis [2 ]
Theodossiadis, Panagiotis [1 ]
机构：
[1] Univ Athens, Dept Ophthalmol 2, Agios Dimitrios, Greece
[2] Ophthalmiatr Athinon, Dept Ophthalmol 2, Athens, Greece
[3] Henry Dunant Hosp, Dept Ophthalmol 2, Athens, Greece
[4] Univ Athens, Dept Ophthalmol 1, Athens, Greece
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2017年 / 58卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3657
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
    Dan Călugăru
    Mihai Călugăru
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 1455 - 1457
  • [2] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
    Irini Chatziralli
    George Theodossiadis
    Marilita M. Moschos
    Panagiotis Mitropoulos
    Panagiotis Theodossiadis
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 1093 - 1100
  • [3] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
    Calugaru, Dan
    Calugaru, Mihai
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (07) : 1455 - 1457
  • [4] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data
    Chatziralli, Irini
    Theodossiadis, George
    Moschos, Marilita M.
    Mitropoulos, Panagiotis
    Theodossiadis, Panagiotis
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (06) : 1093 - 1100
  • [5] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion
    Irini Chatziralli
    George Theodossiadis
    Panagiotis Theodossiadis
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 1459 - 1460
  • [6] Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion
    Chatziralli, Irini
    Theodossiadis, George
    Theodossiadis, Panagiotis
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (07) : 1459 - 1460
  • [7] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study
    Ogura, Yuichiro
    Roider, Johann
    Korobelnik, Jean-Francois
    Holz, Frank G.
    Simader, Christian
    Schmidt-Erfurth, Ursula
    Vitti, Robert
    Berliner, Alyson J.
    Niemeyer, Florian
    Stemper, Brigitte
    Zeitz, Oliver
    Sandbrink, Rupert
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 158 (05) : 1032 - 1038
  • [8] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study
    Calugaru, Dan
    Calugaru, Mihai
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (03) : 607 - 608
  • [9] Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion
    Dedania, Vaidehi
    Ozgonul, Cem
    Besirli, Cagri G.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [10] Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion
    Ozgonul, Cem
    Dedania, Vaidehi S.
    Besirli, Cagri G.
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 34 (04) : 340 - 345
12345